Children running and jumping on a sand dune

2022 Impact Report

See the highlights and impact of Sabin’s work from research & development through vaccine acceptance, demand and uptake.

Impact Highlights

Impact Highlight Timeline

Notable highlights from 2022.

  1. VARN 2022 Conference graphic

    First VARN Meeting

    750 persons from 76 countries registered for the inaugural Vaccination Acceptance Research Network (VARN) conference, held virtually over three days

  2. COVID-19 Vaccine Vials

    $6.3 million Awarded to evaluate effectiveness of fractional doses of COVID-19 vaccine

    Sabin was awarded up to $6.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) for a clinical trial to evaluate the immunogenicity and safety of lower, fractional doses of registered COVID-19 vaccines used as a booster dose. This dose optimizing trial will allow us to understand if smaller doses of COVID-19 vaccines generate similar immune responses to full doses. It will also provide key information as to whether lower doses may have fewer side effects, potentially increasing vaccine acceptance.

  3. Anuradha Gupta

    Anuradha Gupta Joins Sabin as President of Global Immunization

    Veteran public health leader Anuradha Gupta, who spearheaded a host of successful global initiatives to improve the health of women and children and boost vaccine access and uptake, has joined Sabin Vaccine Institute as President of Global Immunization.

  4. December

    29th Albert B. Sabin Gold Medal Ceremony

    Dr. Kathrin Jansen and Dr. Kizzmekia Corbett were honored with the 2022 Albert B. Sabin Awards for their extraordinary contributions to vaccine research.

  5. Sabin Vaccine Institute Ebola Sudan vaccine viles

    Sabin Delivers Ebola Sudan Vaccine to Fight Outbreak in Uganda

    Sabin Vaccine Institute was the first organization to provide the World Health Organization (WHO) its Ebola Sudan vaccine to help with the Ebola Sudan outbreak in Uganda. Approximately 1,100 doses of Sabin’s vaccine were sent to Uganda.

  6. 2022

    Sabin Receives 200M+ BARDA Funding

    This funding will further our Sudan ebolavirus and Marburg vaccine development programs.